Hermite 2012.

Methods	Study design: parallel RCT Study duration: May 2009 to August 2010 Duration of follow‐up: not reported
Participants	Setting: Single centre (2 units) Country: France ICU adult participants ≥18 years with AKI requiring continuous or intermittent HD Number (participants/catheters): treatment group (39/39); control group (39/39) Mean age ± SD (years): treatment group (64 ± 15); control group (65 ± 16) Sex (M/F): treatment group (23/16); control group (30/9) Exclusion criteria: allergy to citrate; pregnancy; liver failure; history of thromboembolic disease
Interventions	Treatment group Citrate solution: 46.7% Control group Saline solution: 10 mL
Outcomes	CRI Probable CRI Catheter malfunction
Notes	Funding source: "This work was financed by the University Hospital of Dijon Clinical Research Division"
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Study was described as randomised, method of randomisation was not reported
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Low risk	This was an open‐label trial; but "as far as possible, the nurses and physicians in the unit in charge of the routine care were blinded to each patient’s treatment."
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcomes were evaluated by an independent clinical event committee who were blinded to participants’ treatment group assignments.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Selective reporting (reporting bias)	Low risk	Describes the outcome according to protocol
Other bias	Low risk	Study appears free of other biases